Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice


Por: Blancas I, Fontanillas M, Conde V, Lao J, Martinez E, Sotelo M, Jaen A, Bayo J, Carabantes F, Illarramendi J, Gordon M, Cruz J, Garcia-Palomo A, Mendiola C, Perez-Ruiz E, Bofill J, Baena-Canada J, Janez N, Esquerdo G, Ruiz-Borrego M

Publicada: 1 jul 2018
Resumen:
This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic breast cancer who had disease progression after receiving anti-estrogen therapy in clinical practice, getting real-world data. Multicenter, retrospective, observational study conducted in Spain. Postmenopausal women with locally advanced/metastatic ER-positive breast cancer who received treatment with fulvestrant 500 mg after progression with a previous anti-estrogen therapy were eligible. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), clinical benefit rate (CBR), duration of clinical benefit (DoCB), and safety profile. A total of 263 women were evaluated (median age, 65.8 years). At a median follow-up of 21.5 months, median PFS and OS were 10.6 and 43.2 months, respectively. PFS according to 1st, 2nd, 3rd, and ae 4th lines were 11.5, 10.6, 9.9, and 8.5 months, respectively (p = 0.0245). PFS in patients with visceral involvement was 10 months vs 10.6 months in patients without visceral involvement (p = 0.6604), 9.6 months in patients with high Ki67 vs 10 months in patients with low Ki67 (p = 0.7224), and 10.2 months in HER2+ patients vs 10.3 months in HER2- patients (p = 0.6809). The CBR was 56.5% and the DoCB was 18.4 months. The most frequently adverse events were injection site pain (10.3%) and musculoskeletal disorders (7.6%). Fulvestrant 500 mg administered in clinical practice was shown to be effective (PFS, 10.6 months; CBR, 56.5%) and well tolerated, in accordance with previous trials.

Filiaciones:
Blancas I:
 Complejo Hosp Univ, Hosp Univ Clin San Cecilio, C Dr Oloriz 16, Granada 18012, Spain

Fontanillas M:
 Hosp Clin Barcelona, Illarroel 170, E-08036 Barcelona, Spain

Conde V:
 Hosp Univ Virgen de las Nieves, Ave Fuerzas Armadas S-N, Granada 18014, Spain

Lao J:
 Hosp Univ Miguel Servet, Paseo Isabel Catolica 1-3, Zaragoza 50009, Spain

Martinez E:
 Hosp Prov Castellon, Ave Dr Clara 19, Castellon de La Plana 12002, Spain

Sotelo M:
 Hosp Univ Clin San Carlos, C Prof Martin Lagos S-N, Madrid 28040, Spain

Jaen A:
 Hosp Jaen, Avda Ejercito Espanol 10, Jaen 23007, Spain

Bayo J:
 Hosp Juan Ramon Jimenez, Ronda Exterior Norte S-N, Huelva 21005, Spain

Carabantes F:
 Hosp Univ Carlos Haya, Ave Carlos Haya S-N, Malaga 29010, Spain

Illarramendi J:
 Complejo Univ Hosp Navarra, Calle Irunlarrea 3, Pamplona 31008, Spain

Gordon M:
 Hosp Jerez, Ronda Circunvalac S-N, Cadiz 11407, Spain

Cruz J:
 Hosp Univ Canarias, Carretera Ofra S-N, Santa Cruz De Tenerife 38320, Spain

Garcia-Palomo A:
 Complejo Univ Asistencial Leon, C Altos Nava S-N, Leon, Spain

Mendiola C:
 Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid 28041, Spain

Perez-Ruiz E:
 Hosp Costa Sol, Autovia A-7,Km 187, Marbella 29603, Spain

Bofill J:
 Hosp Nuestra Senora Valme, Ave Bellavista S-N, Seville 41014, Spain

Baena-Canada J:
 Hosp Univ Puerta del Mar, Ave Ana de Viya 21, Cadiz 11009, Spain

Janez N:
 Hosp Ramon & Cajal, Ctra Colmenar Viejo,Km 9,100, Madrid 28034, Spain

Esquerdo G:
 Clin Benidorm, Ave Alfonso Puchades, Benidorm 03501, Spain

Ruiz-Borrego M:
 Hosp Univ Virgen del Rocio, Ave Manuel Siurot S-N, Seville 41013, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 20 Número: 7
Páginas: 862-869
WOS Id: 000434999000007
ID de PubMed: 29178019

MÉTRICAS